دورية أكاديمية
أعرض في EDS

Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study

التفاصيل البيبلوغرافية
العنوان: Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study
المؤلفون: Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Yuki Funauchi, Takashi Hirai, Masato Yuasa, Yu Matsukura, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake, Atsushi Okawa
المصدر: JBMR Plus, Vol 7, Iss 7, Pp n/a-n/a (2023)
بيانات النشر: Oxford University Press, 2023.
سنة النشر: 2023
المجموعة: LCC:Orthopedic surgery
LCC:Diseases of the musculoskeletal system
مصطلحات موضوعية: FRACTURE RISK ASSESSMENT, SCREENING, ANTIRESORPTIVES, TUMOR‐INDUCED BONE DISEASE, ATYPICAL FEMORAL FRACTURES, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935
الوصف: ABSTRACT Patients on bone‐modifying agents (BMAs) for bone metastases are at risk of atypical femoral fractures (AFFs), which can lead to a sudden deterioration in performance status. In this study, we sought to determine the prevalence of radiographic precursory signs of AFF in patients on oncologic BMAs. Forty‐two patients (23 men, 19 women; mean age 68.8 ± 10.0 years) on oncologic BMAs (zoledronate for >3 years and/or denosumab for >1 year) and without clinical symptoms were enrolled between 2019 and 2021. All patients were receiving denosumab at enrollment and 5 had previously used zoledronate. The mean duration of BMA use was 31.2 ± 18.5 months. Radiographs of both femurs were screened for precursory signs of AFF (e.g., thickening of the lateral cortex). The patients were divided into two groups according to thickening status and compared by duration of BMA use. They were also divided into three groups by duration of BMA use (12–23 months, n = 18; 24–59 months, n = 19; ≥60 months, n = 5), and the prevalence of apparent thickenings was examined. As a result, 18 patients (42.9%) showed minute local or diffuse thickening and 10 (23.8%) showed apparent local thickening. The duration of BMA use was significantly longer in patients with apparent thickening than in those without (47.3 ± 23.6 months [n = 10] versus 26.2 ± 13.5 months [n = 32]; p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2473-4039
Relation: https://doaj.org/toc/2473-4039
DOI: 10.1002/jbm4.10749
URL الوصول: https://doaj.org/article/e57212bf61924c1f8a0e496d8e4c4ba9
رقم الأكسشن: edsdoj.57212bf61924c1f8a0e496d8e4c4ba9
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:24734039
DOI:10.1002/jbm4.10749